The emerging role of anticoagulants targeting Factor XI in thromboembolism management

Laurent Bertoletti; Jean Escal; Lutfi Ozturk; Margaux Geier; Géraldine Poénou

doi:10.1080/17476348.2025.2467463

February 13, 2025Expert Review of Respiratory MedicineOpen Access

The emerging role of anticoagulants targeting Factor XI in thromboembolism management

View Full Paper

Ask AI

Bookmark

Share

Key Points

Review the clinical rationale, development, and therapeutic potential of Factor XI-directed anticoagulants in managing thromboembolic disorders.
Narrative review assessing anticoagulation strategies targeting Factor XI in conditions such as pulmonary embolism, venous thromboembolism prophylaxis, and cancer-associated thrombosis.
Evaluation of perioperative antithrombotic management and bleeding risk trade-offs with novel agents.
Factor XI targeting suppresses pathological thrombosis while preserving fundamental hemostatic pathways required for vascular repair.
Emerging Factor XI inhibitors demonstrate potential to address unmet clinical needs in respiratory medicine, cancer-associated thrombosis, and high-bleeding-risk surgical settings.

No abstract yet

We only have this paper's title and publication details.

Read it at the source

Implication

Review highlights emerging Factor XI inhibitors for thromboembolism prevention in high-risk patients, indicating safer anticoagulation with reduced bleeding risks.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Bertoletti et al. (2025) studied this question.

synapsesocial.com/papers/6a73a3206f409f81651af4fd https://doi.org/10.1080/17476348.2025.2467463

View Full Paper

Ask AI

Bookmark

Share

The emerging role of anticoagulants targeting Factor XI in thromboembolism management

Key Points

No abstract yet

Implication

Discussion

Cite This Study

The emerging role of anticoagulants targeting Factor XI in thromboembolism management

Key Points

No abstract yet

Implication

Discussion

Cite This Study

Keep reading

Keep reading